Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Abstract Background Graft-versus-Host Disease (GvHD) causes significant morbidity and mortality in patients after allogeneic stem cell transplantation. Donor T-cells cause inflammation and tissue damage in GvHD target organs such as liver, gut and skin. Cytokine receptor associated kinases JAK1 and...

Full description

Bibliographic Details
Main Authors: Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke, Robert Zeiser
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Cancer
Subjects:
Steroid-refractory GvHD
Ruxolitinib
JAK inhibitor
Biomarkers
Inflammatory cytokines
Online Access:http://link.springer.com/article/10.1186/s12885-018-5045-7

Internet

http://link.springer.com/article/10.1186/s12885-018-5045-7

Similar Items